Cargando…

The effect of varying analytical methods on estimates of anti-malarial clinical efficacy

BACKGROUND: Analytical approaches for the interpretation of anti-malarial clinical trials vary considerably. The aim of this study was to quantify the magnitude of the differences between efficacy estimates derived from these approaches and identify the factors underlying these differences. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Verret, Wendy J, Dorsey, Grant, Nosten, Francois, Price, Ric N
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679050/
https://www.ncbi.nlm.nih.gov/pubmed/19386088
http://dx.doi.org/10.1186/1475-2875-8-77
_version_ 1782166875069743104
author Verret, Wendy J
Dorsey, Grant
Nosten, Francois
Price, Ric N
author_facet Verret, Wendy J
Dorsey, Grant
Nosten, Francois
Price, Ric N
author_sort Verret, Wendy J
collection PubMed
description BACKGROUND: Analytical approaches for the interpretation of anti-malarial clinical trials vary considerably. The aim of this study was to quantify the magnitude of the differences between efficacy estimates derived from these approaches and identify the factors underlying these differences. METHODS: Data from studies conducted in Africa and Thailand were compiled and the risk estimates of treatment failure, adjusted and unadjusted by genotyping, were derived by three methods (intention to treat (ITT), modified intention to treat (mITT) and per protocol (PP)) and then compared. RESULTS: 29 clinical trials (15 from Africa and 14 from Thailand) with a total of 65 treatment arms (38 from Africa and 27 from Thailand) were included in the analysis. Of the 15,409 patients enrolled, 2,637 (17.1%) had incomplete follow up for the unadjusted analysis and 4,489 (33.4%) for the adjusted analysis. Estimates of treatment failure were consistently higher when derived from the ITT or PP analyses compared to the mITT approach. In the unadjusted analyses the median difference between the ITT and mITT estimates was greater in Thai studies (11.4% [range 2.1–31.8]) compared to African Studies (1.8% [range 0–11.7]). In the adjusted analyses the median difference between PP and mITT estimates was 1.7%, but ranged from 0 to 30.9%. The discrepancy between estimates was correlated significantly with the proportion of patients with incomplete follow-up; p < 0.0001. The proportion of studies with a major difference (> 5%) between adjusted PP and mITT was 28% (16/57), with the risk difference greater in African (37% 14/38) compared to Thai studies (11% 2/19). In the African studies, a major difference in the adjusted estimates was significantly more likely in studies in high transmission sites (62% 8/13) compared to studies in moderate transmission sites (24% 6/25); p = 0.035. CONCLUSION: Estimates of anti-malarial clinical efficacy vary significantly depending on the analytical methodology from which they are derived. In order to monitor temporal and spatial trends in anti-malarial efficacy, standardized analytical tools need to be applied in a transparent and systematic manner.
format Text
id pubmed-2679050
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26790502009-05-08 The effect of varying analytical methods on estimates of anti-malarial clinical efficacy Verret, Wendy J Dorsey, Grant Nosten, Francois Price, Ric N Malar J Research BACKGROUND: Analytical approaches for the interpretation of anti-malarial clinical trials vary considerably. The aim of this study was to quantify the magnitude of the differences between efficacy estimates derived from these approaches and identify the factors underlying these differences. METHODS: Data from studies conducted in Africa and Thailand were compiled and the risk estimates of treatment failure, adjusted and unadjusted by genotyping, were derived by three methods (intention to treat (ITT), modified intention to treat (mITT) and per protocol (PP)) and then compared. RESULTS: 29 clinical trials (15 from Africa and 14 from Thailand) with a total of 65 treatment arms (38 from Africa and 27 from Thailand) were included in the analysis. Of the 15,409 patients enrolled, 2,637 (17.1%) had incomplete follow up for the unadjusted analysis and 4,489 (33.4%) for the adjusted analysis. Estimates of treatment failure were consistently higher when derived from the ITT or PP analyses compared to the mITT approach. In the unadjusted analyses the median difference between the ITT and mITT estimates was greater in Thai studies (11.4% [range 2.1–31.8]) compared to African Studies (1.8% [range 0–11.7]). In the adjusted analyses the median difference between PP and mITT estimates was 1.7%, but ranged from 0 to 30.9%. The discrepancy between estimates was correlated significantly with the proportion of patients with incomplete follow-up; p < 0.0001. The proportion of studies with a major difference (> 5%) between adjusted PP and mITT was 28% (16/57), with the risk difference greater in African (37% 14/38) compared to Thai studies (11% 2/19). In the African studies, a major difference in the adjusted estimates was significantly more likely in studies in high transmission sites (62% 8/13) compared to studies in moderate transmission sites (24% 6/25); p = 0.035. CONCLUSION: Estimates of anti-malarial clinical efficacy vary significantly depending on the analytical methodology from which they are derived. In order to monitor temporal and spatial trends in anti-malarial efficacy, standardized analytical tools need to be applied in a transparent and systematic manner. BioMed Central 2009-04-22 /pmc/articles/PMC2679050/ /pubmed/19386088 http://dx.doi.org/10.1186/1475-2875-8-77 Text en Copyright © 2009 Verret et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Verret, Wendy J
Dorsey, Grant
Nosten, Francois
Price, Ric N
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title_full The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title_fullStr The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title_full_unstemmed The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title_short The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
title_sort effect of varying analytical methods on estimates of anti-malarial clinical efficacy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679050/
https://www.ncbi.nlm.nih.gov/pubmed/19386088
http://dx.doi.org/10.1186/1475-2875-8-77
work_keys_str_mv AT verretwendyj theeffectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT dorseygrant theeffectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT nostenfrancois theeffectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT pricericn theeffectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT verretwendyj effectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT dorseygrant effectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT nostenfrancois effectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy
AT pricericn effectofvaryinganalyticalmethodsonestimatesofantimalarialclinicalefficacy